scholarly journals NGHIÊN CỨU TÌNH TRẠNG NHIỄM MỘT SỐ VIRUS VÀ MỐI LIÊN QUAN ĐẾN ĐÁI THÁO ĐƯỜNG SAU GHÉP THẬN

2021 ◽  
Vol 502 (2) ◽  
Author(s):  
Nguyễn Đức Thuận ◽  
Đặng Thành Chung
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatitis B Virus ◽  
American Diabetes Association ◽  
Hbv Dna ◽  
Hcv Rna ◽  
Realtime Pcr ◽  
Bk Polyomavirus ◽  
B Virus ◽  
Polyomavirus Bk

Mục tiêu: Phân tích tỉ lệ nhiễm một số virus đánh giá mối mối liên quan đến đái tháo đường sau ghép trên đối tượng 3 tháng sau ghép thận. Đối tượng và phương pháp nghiên cứu: Gồm 508 bệnh nhân có thời gian sau ghép thận ≥ 3 tháng được theo dõi và điều trị sau ghép tại BV Việt Đức, từ 09/2017 đến 04/2018. Tất cả các bệnh nhân đều tự nguyện tham gia nghiên cứu. Bệnh nhân được lấy máu, và nước tiểu vào buổi sáng trước khi ăn và uống thuốc ức chế miễn dịch. Xét nghiệm sinh học phân tử (Realtime PCR) phát hiện sự có mặt của các loại virus viêm gan B (hepatitis B virus - HBV), virus viêm gan C (hepatitis C virus - HCV), cytomegalovirus (CMV), BK polyomavirus (BK) trong máu của bệnh nhân, riêng virus BK còn được đánh giá sự có mặt trong nước tiểu. Chẩn đoán đái tháo đường sau ghép tạng dựa trên tiêu chuẩn của Hiệp hội Đái tháo đường Hoa Kỳ (ADA - American Diabetes Association). Kết quả: Trong 508 đối tượng nghiên cứu, trong máu có: 28/436 bệnh nhân (6,42%) có HBV-DNA dương tính; 24/444 (5,54%) bệnh nhân HCV-RNA dương tính; 35/395 (8,86%) bệnh nhân CMVdương tính; 30/493 (6,09%) BK máu dương tính; Trong nước tiểu có 150/500 (30 %) BK dương tính; 40/508 (7,87%) bệnh nhân đồng nhiễm ít nhất 2 loại virus. Không có sự khác biệt về tỉ lệ NODAT giữa những người bị nhiễm các loại virus kể trên với người không bị nhiễm. Kết luận: Kết quả của nghiên cứu này cung cấp số liệu về tỉ lệ nhiễm các loại virus HBV, HCV, CMV và BK trên một số lớn đối tượng và cho thấy chưa có mối liên quan với NODAT ở bệnh nhân 3 tháng sau ghép thận.

scholarly journals Effect of Multiple Freeze-Thaw Cycles on Hepatitis B Virus DNA and Hepatitis C Virus RNA Quantification as Measured with Branched-DNA Technology

1999 ◽  
Vol 37 (6) ◽  
pp. 1683-1686 ◽  
Author(s):  
Mel Krajden ◽  
James M. Minor ◽  
Oretta Rifkin ◽  
Lorraine Comanor
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Hbv Dna ◽  
Hcv Rna ◽  
Freeze Thaw ◽  
Rna Quantification ◽  
B Virus ◽  
Rna Levels

Quantification of hepatitis B virus (HBV) DNA and hepatitis C virus (HCV) RNA often is performed in specimens that have been frozen and thawed more than once. To ensure optimal therapeutic and prognostic value, it is important to establish whether viral load measurements are affected by repeated freeze-thaw (FT) cycles. We therefore evaluated the effect of multiple FT cycles on HBV DNA and HCV RNA quantification by testing serum specimens subjected to one (baseline), two, four, and eight FT cycles with the appropriate Chiron Quantiplex assay. Linear regression analysis showed minor increases of 1.7% per FT cycle for both HBV DNA and HCV RNA. The rise in HCV RNA levels was more pronounced among low-concentration samples, since further analysis revealed an increase of 3.2% per FT cycle among samples with 0.2 to 3.86 Meq of HCV RNA per ml. Given that the coefficient of variation for the Quantiplex assays is generally 10 to 15%, the minor increases in HBV DNA and HCV RNA levels with progressive FT cycles for the specimens tested were recognized only because analysis of variance revealed a statistically significant trend (P < 0.05). Due to the minor statistical trend, the clinical impact for individual patient specimens is likely to be limited, but it may deserve further study. In conclusion, the concentration of HBV DNA and HCV RNA in serum specimens subjected to up to eight short-term FT cycles was stable.

scholarly journals Hepatitis B Virus DNA in Sera of Blood Donors and of Patients Infected with Hepatitis C Virus and Human Immunodeficiency Virus

2003 ◽  
Vol 10 (4) ◽  
pp. 718-720 ◽  
Author(s):  
Fernando Lopes Gonçales ◽  
Josiane Silveira Felix Pereira ◽  
Claudia da Silva ◽  
Glaucimari Roberto Thomaz ◽  
Maria Helena Postal Pavan ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Blood Donors ◽  
Hbv Dna ◽  
Serum Samples ◽  
B Virus ◽  
Immunodeficiency Virus

ABSTRACT With the use of PCR, we searched for hepatitis B virus (HBV) DNA in serum samples from 415 HBsAg-negative, anti-HBc-positive patients: 150 were blood donors, 106 had only hepatitis C virus (HCV) infection, and 159 had human immunodeficiency virus (HIV) infection (of which 88 were HCV positive and 71 were HCV negative). HBV DNA was detected in 4% of blood donors, 3.4% of HIV- and HCV-positive patients, and 24% of HCV-positive patients.

scholarly journals Hepatitis C Virus and Hepatitis B Virus Co-Infection

Viruses ◽  
2020 ◽  
Vol 12 (7) ◽  
pp. 741
Author(s):  
Yi-Fen Shih ◽  
Chun-Jen Liu
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Interferon Response ◽  
Hcv Rna ◽  
Hbv Reactivation ◽  
Post Intervention ◽  
Populations At Risk ◽  
B Virus

Hepatitis C virus (HCV) and hepatitis B virus (HBV) co-infection can be encountered in either virus endemic countries. Co-infection can also be found in populations at risk of parenteral transmission. Previous studies demonstrated a high risk of liver disease progression in patients with HCV/HBV co-infection; thus, they should be treated aggressively. Previous evidence recommended therapy combining peginterferon (pegIFN) alfa and ribavirin for co-infected patients with positive HCV RNA. Recent trials further advise using direct-acting antivirals (DAAs) for the clearance of HCV in the co-infected patients. Reactivation of HBV has been observed in patients post-intervention, with higher risks and earlier onset in those having had HCV cured by DAA- versus pegIFN-based therapy. The mechanism of HBV reactivation is an interesting but unsolved puzzle. Our recent study revealed that in vitro HBV replication was suppressed by HCV co-infection; HBV suppression was attenuated when interferon signaling was blocked. In vivo, the HBV viremia, initially suppressed by the presence of HCV super-infection, rebounded following HCV clearance by DAA treatment and was accompanied by a reduced hepatic interferon response. In summary, major achievements in the treatment of HCV/HBV co-infection have been accomplished over the past 20 years. Future clinical trials should address measures to reduce or prevent HBV reactivation post HCV cure.

scholarly journals Hepatitis C virus and hepatitis B virus bind to heparin: purification of largely IgG-free virions from infected plasma by heparin chromatography

2005 ◽  
Vol 86 (3) ◽  
pp. 677-685 ◽  
Author(s):  
Astrid Zahn ◽  
Jean-Pierre Allain
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Human Plasma ◽  
Hcv Rna ◽  
Dependent Manner ◽  
Free Virus ◽  
B Virus ◽  
One Step

Binding to heparin of hepatitis C virus (HCV) and hepatitis B virus (HBV) from chronic carriers was investigated. Eighty per cent of HCV RNA from an agammaglobulinaemic patient (IgG-free virus) was retained on immobilized heparin and eluted with ⩾0·4 M NaCl, in contrast to ∼20 % from immunocompetent chronic carriers (with ⩽8 % IgG-free virus). Increased binding to heparin of the HCV fraction that was not retained by a protein G column suggested that antibodies complexed to the virions partially inhibited the interaction. A higher proportion (15–80 %) of HBV from chronic carriers bound to heparin and eluted with ⩾0·4 M NaCl. After washing of the heparin columns with 0·3 M NaCl, <1 % of total plasma proteins co-eluted with HCV or HBV. By this one-step heparin chromatography, without ultracentrifugation, IgG-free HCV and IgG-free HBV were preferentially purified from human plasma by 1000-fold and greater than 500-fold, respectively. Following assessment with an anti-E2 envelope protein antibody, the amount of immunoprecipitated HCV particles after heparin purification was similar to that in the original plasma, suggesting that undamaged virions were purified. This was further supported by heparin-purified HCV binding to lymphocyte cell lines in a dose-dependent manner. Intact HBV particles were detected by electron microscopy. It was concluded that HCV and HBV from chronically infected patients bind to heparin, the closest homologue of liver heparan sulfate, and that heparin chromatography is an efficient and gentle method for purifying these viruses from human plasma. In the absence of cell-culture systems or alternative robust purification methods, heparin chromatography may help greatly in binding and infectivity studies.

Alkoholabstinenz allein verbessert die Leberfunktion und verlängert das Überleben bei der alkoholischen Lebererkrankung!

2016 ◽  
Vol 62 (6) ◽  
pp. 396-400 ◽  
Author(s):  
Helmut K. Seitz ◽  
Tatjana Arslic-Schmitt
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
B Virus ◽  
Alkoholische Lebererkrankung ◽  
Alkoholische Steatohepatitis

Zusammenfassung. Zielsetzung: Im Folgenden soll dargelegt werden, dass Alkoholkarenz sowohl die Leberfunktion als auch das Überleben in jedem Stadium einer alkoholischen Lebererkrankung günstig beeinflusst. Ergebnisse: Täglicher Alkoholkonsum von mehr als 25 Gramm reinen Alkohols, etwas mehr als ¼ Liter Wein beim Mann und etwa die Hälfte bei der Frau sind, mit einem erhöhten Risiko für eine alkoholische Lebererkrankung (ALE) behaftet. Die ALE besteht aus einem breiten Spektrum von histopathologischen Veränderungen. Sie beginnt immer mit einer alkoholischen Fettleber, die sich in eine alkoholische Steatohepatitis weiterentwickeln kann. Fortgeschrittene Formen der ALE beinhalten die Leberfibrose, die Leberzirrhose und das hepatozelluläre Karzinom. In der Behandlung jeder Form der ALE ist die Alkoholabstinenz von zentraler Bedeutung. Ein Großteil der alkoholischen Fettlebern bildet sich unter Alkoholkarenz oder sogar Alkoholreduktion zurück. Die alkoholische Hepatitis, ein klinisches Syndrom mit hoher Mortalität, führt ohne Alkoholkarenz innerhalb von Tagen und Wochen zum Tode. Darüber hinaus ist selbst die Leberfibrose (perivenös und perisinusoidal) unter Alkoholkarenz rückbildungsfähig. Bei allen Formen der fortgeschrittenen ALE (kompensiert und nicht-kompensierte Leberzirrhose) wird die Mortalität durch Alkoholkarenz oder signifikante Reduktion im Gegensatz zum fortgesetzten Alkoholkonsum signifikant verringert. Selbst Patienten mit alkoholischer Leberzirrhose können über mehr als 20 Jahre ohne Komplikationen weiterleben, wenn sie komplett auf Alkohol verzichten. Schlussfolgerung: Im Vergleich zu Leberzirrhose anderer Ätiologie, wie zum Beispiel Zirrhosen, die durch das Hepatitis-B Virus oder das Hepatitis-C Virus verursacht sind, haben alkoholische Leberzirrhosen unter Alkoholkarenz eine wesentlich bessere Prognose. Damit ist Alkoholkarenz eine gute Therapie und der Erfolg jeder anderen neuen Therapie muss mit Alkoholkarenz verglichen werden.

Sign in / Sign up

Export Citation Format

Share Document